Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies

Table 3

Pre- and posttreatment serum VEGF levels in different hematological malignancy.

	Serum VEGF levels before treatment (pg/mL); mean ± standard deviation	Serum VEGF levels after treatment (pg/mL); mean ± standard deviation	value
AML	78.75 ± 33.83	100.91 ± 68	0.329
ALL	163.64 ± 95.81	86.57 ± 60.99	0.008
CML	1011.5 ± 789.09	294.84 ± 401.17	0.037
CLL	157.50 ± 17.67	75 ± 14.14	0.019
MM	229.2 ± 81.90	125.1 ± 59.56	0.002
NHL	105 ± 21.21	79.50 ± 21.92	0.012

AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphoid leukemia; MM, multiple myeloma; NHL, Non-Hodgkin’s Lymphoma.